Eisai Co., Ltd. (OTCMKTS:ESALY) Expected to Post FY2023 Earnings of $1.15 Per Share

Eisai Co., Ltd. (OTCMKTS:ESALY – Get Rating) – Jefferies Financial Group issued their FY2023 earnings per share (EPS) estimates for Eisai in a research note issued to investors on Tuesday, July 26th. Jefferies Financial Group analyst S. Barker anticipates that the company will post earnings per share of $1.15 for the year. The consensus estimate for Eisai’s current full-year earnings is $1.57 per share. Jefferies Financial Group also issued estimates for Eisai’s FY2024 earnings at $1.49 EPS, FY2025 earnings at $1.25 EPS and FY2026 earnings at $1.68 EPS.

Eisai Price Performance

Eisai stock opened at $45.87 on Friday. Eisai has a one year low of $36.88 and a one year high of $85.10. The business has a fifty day moving average price of $42.39 and a 200-day moving average price of $45.99. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.04 and a quick ratio of 1.73. The firm has a market capitalization of $13.15 billion, a P/E ratio of 29.98, a PEG ratio of 2.17 and a beta of 0.39.

Eisai (OTCMKTS:ESALY – Get Rating) last released its earnings results on Friday, May 13th. The company reported ($0.37) earnings per share (EPS) for the quarter. Eisai had a return on equity of 6.46% and a net margin of 6.53%. The firm had revenue of $1.64 billion during the quarter.

Eisai Company Profile

(Get Rating)

Eisai Co, Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures.

Recommended Stories

• Get a free copy of the StockNews.com research report on Eisai (ESALY)
• MarketBeat: Week in Review 7/25 – 7/29
• Procter’s Earnings Start To Show Weakness In Q4
• The One Question You Have to Ask Before Investing in INTC Stock
• Home Depot: A Beautiful Boring Stock to Navigate a Bear Market
• Could CRISPR Therapeutics be a Moonshot Hiding in Plain Sight?

Want More Great Investing Ideas?